10x Genomics (NASDAQ:TXG) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS

10x Genomics (NASDAQ:TXG) issued its quarterly earnings results on Wednesday. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08), Zacks reports. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. 10x Genomics updated its FY 2025 guidance to EPS.

10x Genomics Stock Up 1.5 %

Shares of TXG traded up $0.18 during midday trading on Wednesday, hitting $12.00. The company had a trading volume of 4,201,812 shares, compared to its average volume of 2,328,019. 10x Genomics has a 52 week low of $11.55 and a 52 week high of $51.22. The company’s 50 day moving average price is $14.90 and its 200 day moving average price is $17.50. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -7.84 and a beta of 1.85.

Analyst Ratings Changes

A number of brokerages recently weighed in on TXG. UBS Group reduced their target price on 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th. JPMorgan Chase & Co. dropped their price objective on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, October 30th. The Goldman Sachs Group decreased their price target on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research report on Wednesday, October 30th. Morgan Stanley reduced their price objective on 10x Genomics from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Finally, Citigroup dropped their target price on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, seven have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.79.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.